Cara Therapeutics (CARA) Misses Q3 EPS by 4c
Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.38), $0.04 worse than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.38), $0.04 worse than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.